Vergoeding 2020-2024 voor ATC-subgroep J05AG : Niet-nucleoside reverse-transcriptaseremmers
- Raming voor de totale Zvw-populatie
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| J05AG01 Nevirapine (Viramune ®) | 1.508.700 | 1.066.100 | 873.830 | 1.000.300 | 804.240 |
| J05AG03 Efavirenz | 370.020 | 349.750 | 222.640 | 109.540 | 86.290 |
| J05AG04 Etravirine (Intelence ®) | 498.550 | 427.590 | 396.470 | 347.260 | 306.340 |
| J05AG05 Rilpivirine (Rekambys ®) | 270.420 | 392.020 | 1.174.600 | 2.213.100 | 2.407.700 |
| J05AG06 Doravirine (Pifeltro ®) | 272.680 | 510.480 | 752.700 | 855.200 | 1.023.900 |
| Totaal | 2.920.370 | 2.745.940 | 3.420.240 | 4.525.400 | 4.628.470 |